期刊
JOURNAL OF INFECTIOUS DISEASES
卷 224, 期 5, 页码 749-753出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiab361
关键词
SARS-CoV-2; antivirals; molnupiravir; VoC; hamsters; coronavirus; B.1.351
资金
- Katholieke Universiteit Leuven/Universitair Ziekenhuis Leuven COVID19 fund
- Fonds Wetenschappelijk Onderzoek COVID-19 call [G0G4820N]
- European Union Horizon 2020 Research and Innovation Program SCORE Project [101003627]
- Bill and Melinda Gates Foundation [INV-00636]
The emergence of SARS-CoV-2 variants of concern has worsened the COVID-19 pandemic, with current monoclonal antibodies and vaccines showing reduced efficacy against some of these variants. However, antivirals targeting conserved proteins of SARS-CoV-2 are likely to remain effective. Research on molnupiravir has shown effectiveness against different variants, highlighting its potential in combating current and future variants.
The emergence of SARS-CoV-2 variants of concern (VoCs) has exacerbated the COVID-19 pandemic. Currently available monoclonal antibodies and vaccines appear to have reduced efficacy against some of these VoCs. Antivirals targeting conserved proteins of SARS-CoV-2 are unlikely to be affected by mutations arising in VoCs and should therefore be effective against emerging variants. We here investigate the efficacy of molnupiravir, currently in phase 2 clinical trials, in hamsters infected with Wuhan strain or B.1.1.7 and B.1.351 variants. Molnupiravir proved to be effective against infections with each of the variants and therefore may have potential combating current and future emerging VoCs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据